COMMUNIQUÉS West-GlobeNewswire
-
MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026
28/07/2026 -
National Center for Cannabis Research and Education at the University of Mississippi and Southern Sky Brands Launch CBD Sleep Study
28/07/2026 -
The Cooperative of American Physicians Promotes Simon Russell to Vice President of Underwriting
28/07/2026 -
Healthcare Executives Signal Growing Strategic Value of Laboratory Services, Siemens Healthineers Survey Finds
28/07/2026 -
Medical Grade Physiotherapy & Wellness Brings Extensive Experience to WSIB and MVA Physiotherapy Care in Burlington, Ontario
29/07/2026 -
CancerVax Named a Top Preclinical Biotech Company of 2026 by Life Sciences Review
28/07/2026 -
Seer Stockholders Vote to Re-Elect All Seven of Seer’s Director Nominees at 2026 Annual Meeting
28/07/2026 -
Scientists Turn COVID-19 Immune Memory into a Powerful New Ally Against Cancer
28/07/2026 -
Health Catalyst to Announce Second Quarter 2026 Operating Results and Host Conference Call on Thursday, August 6, 2026
28/07/2026 -
PETVIVO HOLDINGS ANNOUNCES TERMINATION AND SETTLEMENT AGREEMENT WITH VETSTEM
28/07/2026 -
Corporate Updates – NurExone appoints Mr. David Stolick to the Board of Directors
28/07/2026 -
Chemed Reports Second-Quarter 2026 Results
28/07/2026 -
Alamar Biosciences Launches NULISAseq™ Immune 340 Panel for Comprehensive Profiling of the Immune Proteome
28/07/2026 -
Pennant Announces Second Quarter 2026 Earnings Release and Call
28/07/2026 -
AscellaHealth Appoints Industry Veteran Johanna van Nijkerk as Vice President of Business Development to Advance National Accounts and Drive Growth of AscellaOne
28/07/2026 -
RECORDATI: SOLID MOMENTUM OF THE GROUP CONTINUES FIRST HALF 2026. NET REVENUE +6.6%, EBITDA +8.8%, ADJUSTED NET INCOME +6.7%
28/07/2026 -
EssilorLuxottica: Q2/H1 2026 Results - Solid revenue trajectory at +9.7% in H1, with Q2 at +8.7%. Increasing profitability, with Adj. Operating Profit +15%.
28/07/2026 -
EssilorLuxottica: Résultats T2/S1 2026 - Trajectoire solide du chiffre d’affaires à +9,7 % au S1, avec un T2 à +8,7 %. Rentabilité en hausse, avec un résultat opérationnel ajusté progressant de +15 %.
28/07/2026 -
Eurobio Scientific: Premier semestre 2026, Continuation de la transformation stratégique
28/07/2026
Pages